<DOC>
	<DOCNO>NCT02520908</DOCNO>
	<brief_summary>Epidermotropic T-cell lymphoma ( ETCL ) , i.e . mycosis fungoides ( MF ) leukemic variant , Sézary syndrome , frequent subtypes cutaneous T-cell lymphoma . MF typically run indolent course early stage . By contrast , advanced-stage ETCLs share bad prognosis : Patients usually show early relapse chemotherapy , prolong complete remission exceptionally occur quality life severely affect . Several publication report durable response follow allogeneic hematopoietic stem cell transplantation ( HSCT ) advanced-stage ETCLs . This study aim investigate role allogeneic HSCT treat advanced-stage ETCLs . An observational , prospective , multicenter , control study compare outcomes patient receive reduced-intensity condition allogeneic HSCT sibling 10/10 HLA-matched unrelated donor patient receive standard care patient advanced-stage ETCL poor prognostic feature , perform . Patients include time donor search irrespective result , compare donor versus donor basis . It observational study since intervention make except comparison outcome group receive usual care ( HSCT donor available , ) .</brief_summary>
	<brief_title>Benefit Allogeneic Haematopoietic Stem Cells Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage Poor Prognosis</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Age ≥ 18 ≤ 65 year Histopathologically confirm diagnosis International Society Cutaneous Lymphomas ( ISCL ) / European Organisation Research Treatment Cancer ( EORTC ) stage IIB , III , IVA IVB ETCL Complete partial response lymphoma ( defined international ISCLEORTC criterion time inclusion Written inform consent give patient Contraception woman childbearing age Hematopoietic stem cell donor search underway And least one three follow criterion : Refractoriness early relapse ( i.e . within one year ) least one line systemic chemotherapy ( include skindirected therapy , methotrexate , interferonalpha , oral retinoids ) Early histological largecell transformation , i.e . within two year follow ETCL diagnosis Histologically proven nodal ( ISCL / EORTC N3 ) extracutaneous visceral involvement lymphoma Prior allogeneic HSCT Other progressive neoplastic disease Progressive psychotic disease Left ventricular ejection fraction &lt; 50 % ( determine transthoracic echocardiography ) Pulmonary disease FEV1 , FVC DLCO &lt; 30 % expect corrected hemoglobin . Creatinine clearance &lt; 50 ml/min require dialysis Transaminases bilirubin &gt; twofold normal value absence liver involvement lymphoma Pregnant breastfeed woman Patient health coverage Patient guardianship curatorship HTLV1 lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>